eMabs - Engineering Monoclonal Antibodies for Research

posted on 08/12/2011

•   

Ready-made, highly specific, renewable antibody reagents for lifes science researchers

Ready-made, highly specific, renewable supply of antibody reagents that work in your assays

According to the research report Global Monoclonal Antibody Market Analysis, the global monoclonal antibodies market witnessed an annual growth rate of around 13% during 2008-2009. Presently, large pharmaceutical companies are investing heavily both in developing such drugs internally and acquiring monoclonal antibody candidates from other companies. However, target-based research is still hindered, even impossible at times, due to the lack of a consistent supply of monoclonal antibody reagents that will work with their assays.Thanks to the researchers at Abazyme, LLC, they have developed a patent-pending custom engineered monoclonal antibody service for research applications called eMabs  Their promise is to deliver highly-specific, high-performance, readily renewable recombinant antibodies to your targets that work in your assays with the flexibility and potential for further engineering for additional applications.It works because they start with either your target or hybridoma.  With the target, they create hybridomas which are immediately cloned & sequenced. With your hybridomas, they clone and sequence the DNA.  They then take the IG DNA sequence and create a stable expression vector.  They can produce your antibody, or you can, in a simple HEK293 cell. You have complete control over your vital research. Another plus, your supply is "freezer proof."The bottom line: They have been in your shoes & have shared the frustration with current research antibodies.  They are not only creating new & better antibodies for you the customer, but they are also fixing "broken" antibodies using their recombinant technology.Using recombinant antibodies has significant advantages compared with the conventional antibody; therefore, its use is becoming more popular now days due to the fact that no animals are needed in the manufacturing procedure of the recombinant antibodies, in addition, the manufacturing time is relatively short compared with the conventional method. Moreover, the quality of the final product is higher than those of the non-recombinant method.